Nanjing Well Pharmaceutical Co Ltd (603351) — Capital Reinvestment Ratio
Nanjing Well Pharmaceutical Co Ltd (603351) has a Capital Reinvestment Ratio of 0.15x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥69.51 Million) in capital expenditures (CN¥10.29 Million). Check tangible net worth ratio of Nanjing Well Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Nanjing Well Pharmaceutical Co Ltd Capital Reinvestment Ratio (2014–2025)
This chart tracks Nanjing Well Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see Nanjing Well Pharmaceutical Co Ltd cash flow conversion.
Annual Capital Reinvestment Ratio for Nanjing Well Pharmaceutical Co Ltd (2014–2025)
Year-by-year Capital Reinvestment Ratio for Nanjing Well Pharmaceutical Co Ltd from 2014 to 2025. See Nanjing Well Pharmaceutical Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | CN¥238.24 Million | CN¥52.18 Million | ▼ -5.6% |
| 2024 | 0.23x | CN¥221.79 Million | CN¥51.46 Million | ▼ -61.8% |
| 2023 | 0.61x | CN¥120.24 Million | CN¥73.07 Million | ▼ -71.7% |
| 2022 | 2.15x | CN¥108.99 Million | CN¥233.90 Million | ▼ -29.1% |
| 2020 | 3.03x | CN¥93.30 Million | CN¥282.44 Million | ▲ +225.5% |
| 2019 | 0.93x | CN¥129.69 Million | CN¥120.62 Million | ▼ -22.9% |
| 2018 | 1.21x | CN¥63.76 Million | CN¥76.95 Million | ▲ +35.8% |
| 2017 | 0.89x | CN¥71.27 Million | CN¥63.35 Million | ▲ +64.4% |
| 2016 | 0.54x | CN¥128.18 Million | CN¥69.31 Million | ▼ -43.0% |
| 2015 | 0.95x | CN¥81.14 Million | CN¥76.92 Million | ▼ -20.1% |
| 2014 | 1.19x | CN¥74.62 Million | CN¥88.54 Million | — |